🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07599046
Starting soon Not applicable

Fecal Microbiota Transplantation (FMT) Combined With Calorie-Restricted Diet and Semaglutide in Patients With Obesity and Type 2 Diabetes

NCT07599046 · tracked via the Priya Life Science China tracker
Sponsor
Eighth Affiliated Hospital, Sun Yat-sen University
Phase
Not applicable
Started
2026-04-30
Last updated
2026-05-20

Condition(s) studied

Obesity Type 2 Diabetes Mellitus

Investigational drug(s) / intervention(s)

Fecal microbiota transplantation (FMT)Semaglutide (1 Mg Dose)Calorie-restricted diet

Fecal microbiota transplantation (FMT): Donor Selection: Healthy lean donors with BMI \<23 kg/m² will be selected following rigorous health screening. Capsule Preparation: Donor fecal samples will be homogenized, filtered to remove debris, lyophilized, and encapsulated in enteric-coated capsules. Oral FMT capsule dosage: 10 capsules per dose, once daily, for 6 consecutive days each month.

Semaglutide (1 Mg Dose): Semaglutide 1.0 mg subcutaneous injection once weekly

Calorie-restricted diet: Daily caloric intake will be individualized based on physical activity level: 25 kcal/kg/day for individuals with light-to-moderate physical activity and 30 kcal/kg/day for those with heavy physical activity.

Study summary

Investigation of the efficacy of fecal microbiota transplantation added to calorie-restricted diet and semaglutide versus calorie-restricted diet and semaglutide alone for weight loss and metabolic improvement in patients with moderate to severe obesity and type 2 diabetes mellitus.

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: 1. Age 18-60 years; 2. Body mass index (BMI) ≥30 kg/m² and \<40 kg/m²; 3. Duration of type 2 diabetes mellitus \<1 year; 4. Non-smoker or smoking cessation \>3 months; 5. Voluntary signed informed consent with commitment to complete the entire study. Exclusion Criteria: 1. Complicated with severe hepatic or renal insufficiency (alanine aminotransferase/aspartate aminotransferase \[ALT/AST\] \>3 times the upper limit of normal, or estimated glomerular filtration rate \[eGFR\] \<60 mL/min/1.73 m²); 2. Inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), or other organic intestinal diseases; autoimmune diseases, malignancies, or active infections; 3. Medication and intervention exclusions: Use of α-glucosidase inhibitors, antibiotics, proton pump inhibitors (PPIs), or probiotics/prebiotics within the past 3 months; bariatric surgery within the past 6 months; long-term use of immunosuppressants or glucocorticoids; 4. Others: Pregnant or lactating women; currently participating in other clinical trials.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Eighth Affiliated Hospital, Sun Yat-sen University Shenzhen Guangdong

More Eighth Affiliated Hospital, Sun Yat-sen University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07599046 on ClinicalTrials.gov ↗ ← All trials in China